LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

Search

Certara Inc

Slēgts

SektorsVeselības aprūpe

8.99 -1.21

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

8.96

Max

9.11

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

1.5M

Pārdošana

46K

105M

P/E

Sektora vidējais

124.857

76.798

EPS

0.14

Peļņas marža

1.458

Darbinieki

1,487

EBITDA

-6.5M

23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+38.48% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-487M

1.4B

Iepriekšējā atvēršanas cena

10.2

Iepriekšējā slēgšanas cena

8.99

Ziņu noskaņojums

By Acuity

94%

6%

359 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 22. dec. 23:54 UTC

Galvenie tirgus virzītāji

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

2025. g. 22. dec. 19:08 UTC

Iegādes, apvienošanās, pārņemšana

Correction to Alphabet to Buy Intersect Article

2025. g. 22. dec. 17:21 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

2025. g. 22. dec. 16:46 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet to Buy Intersect for $4.75 Billion in Cash

2025. g. 22. dec. 23:50 UTC

Tirgus saruna

Nikkei May Decline as Yen Rebounds -- Market Talk

2025. g. 22. dec. 23:42 UTC

Tirgus saruna

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

2025. g. 22. dec. 22:31 UTC

Peļņas

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

2025. g. 22. dec. 22:31 UTC

Peļņas

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

2025. g. 22. dec. 22:30 UTC

Peļņas

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

2025. g. 22. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 22. dec. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 22. dec. 21:37 UTC

Iegādes, apvienošanās, pārņemšana

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

2025. g. 22. dec. 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

2025. g. 22. dec. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

Capricorn to Acquire Prospective Package From Tempest Minerals

2025. g. 22. dec. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

2025. g. 22. dec. 20:54 UTC

Iegādes, apvienošanās, pārņemšana

Middle West Partners Buys Paul Stuart From Mitsui & Co.

2025. g. 22. dec. 20:52 UTC

Iegādes, apvienošanās, pārņemšana

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

2025. g. 22. dec. 20:09 UTC

Tirgus saruna

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

2025. g. 22. dec. 19:56 UTC

Tirgus saruna

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

2025. g. 22. dec. 19:49 UTC

Iegādes, apvienošanās, pārņemšana

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

2025. g. 22. dec. 19:23 UTC

Tirgus saruna

Mexico's Inflation Seen Easing in Early December -- Market Talk

2025. g. 22. dec. 19:23 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 22. dec. 19:02 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 22. dec. 19:02 UTC

Tirgus saruna

Precious Metals Climb to New Heights -- Market Talk

2025. g. 22. dec. 18:45 UTC

Tirgus saruna

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

2025. g. 22. dec. 18:30 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

2025. g. 22. dec. 18:23 UTC

Iegādes, apvienošanās, pārņemšana

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

2025. g. 22. dec. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 22. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 22. dec. 17:06 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

38.48% augšup

Prognoze 12 mēnešiem

Vidējais 12.56 USD  38.48%

Augstākais 16 USD

Zemākais 9 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

6

Pirkt

5

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

359 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat